ClinicalTrials.Veeva

Menu
T

The University of Sydney | Save Sight Institute

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lampalizumab
APL-2
Latanoprost
Aflibercept
ranibizumab
Bevacizumab
KIO-301
Xalatan

Parent organization

This site is a part of The University of Sydney

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 14 total trials

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa (ABACUS-2)

The goal of the study is to investigate the safety, tolerability and efficacy of up to 3 doses of KIO-301 administered by intravitreal (IVT) injectio...

Not yet enrolling
Retinitis Pigmentosa
Drug: 100 μg KIO-301
Other: Placebo (Sterile Saline)

The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in...

Enrolling
Geographic Atrophy Secondary to Age-related Macular Degeneration
Intermediate AMD
Device: i-Lumen AMD

Trial sponsors

Roche logo
N
U
A
Bayer logo
Genentech logo
K
Viatris logo
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems